Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites

Authors

  • Lihui Deng,

    1. Center of Infectious Diseases, West China Hospital of Sichuan University
    2. Division of Infectious Diseases, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan Province, China
    Search for more papers by this author
  • Hong Tang

    Corresponding author
    1. Center of Infectious Diseases, West China Hospital of Sichuan University
    2. Division of Infectious Diseases, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan Province, China
      Professor Hong Tang, Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China. Email: htang6198@hotmail.com
    Search for more papers by this author

Professor Hong Tang, Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China. Email: htang6198@hotmail.com

Abstract

Nucleos(t)ide analogs (NAs) have become the mainstream drugs for the treatment of chronic hepatitis B virus infection. Drug resistance to NAs, however, has posed a major obstacle in obtaining sustained viral suppression. Standardized definitions of terms and nomenclature in discussing NAs resistance have been proposed. Drug resistance to NAs is produced by a combination of viral, host and antiviral drug factors. A detailed understanding of the mechanisms and effects of mutation sites that cause resistance to NAs is important for the design of rational treatment and management of patients with existing drug resistance.

Ancillary